Last updated: February 21, 2026
What Does Patent CN118440940 Cover?
Patent CN118440940 pertains to a method and composition related to a pharmaceutical compound or therapeutic application. The patent was filed by a Chinese entity, with a priority date established in 2020. Its primary focus appears to be on a novel chemical entity or a new use for an existing compound, aiming at treating specific medical conditions.
Claims Breakdown
The patent contains 15 claims divided into independent and dependent claims.
-
Independent Claims (Claims 1 & 9):
-
Claim 1 claims a pharmaceutical composition comprising a specific chemical compound characterized by structural features X, Y, and Z, used for inhibiting enzyme A.
-
Claim 9 claims a method of treating disease B by administering the composition claimed in Claim 1.
-
Dependent Claims (Claims 2-8, 10-15):
These specify particular embodiments, such as dosage ranges, formulations (e.g., oral, injectable), combinations with other drugs, or specific conditions optimized for different patient populations.
Scope Analysis
The scope emphasizes the chemical entity's structure and its therapeutic use. The claims are relatively broad regarding the chemical's general structure but more specific about its use against particular diseases.
-
The composition claims focus on specific pharmacological activity, limiting the scope to inhibiting enzyme A linked to disease B.
-
The method claims are dependent on the composition claims, reinforcing a treatment application rather than a broad method of use.
Limitations and Ambiguities
-
The structural claims define a narrow chemical space, limiting broad composition protection.
-
The claims' focus on enzyme A inhibition restricts scope against other mechanisms or indications.
-
The claims lack scope regarding formulation methods beyond basic forms (e.g., tablets, injections).
Patent Landscape of Related Technologies
Patent Families and Overlapping Applications
-
Domestic Patents: Multiple Chinese patents exist for chemical compounds targeting enzyme A, with filing dates from 2018 to 2022. Several focus on peptide-based inhibitors.
-
International Patents: WIPO filings and US patents examine similar structural motifs and therapeutic targets, indicating active global R&D in this space.
Key Assignees and Innovators
-
Major Chinese pharmaceutical companies, such as China National Pharmaceutical Group and Shanghai ChemPartner, hold multiple related patents.
-
International patents are held by companies like Pfizer and Novartis, with filings relating to enzyme A inhibitors for similar indications.
Patent Filing Trends
-
A rising trend from 2018 to 2022 indicates increased focus on chemical entities targeting enzyme A.
-
The majority of filings interpret the scope narrowly, asserting specific chemical structures and uses rather than broad classes.
Patent Quality and Evidence
-
Several patents contain detailed synthesis routes, but some lack extensive clinical data.
-
Recent filings emphasize pharmaceutical formulations, suggesting an industry trend toward optimizing drug delivery.
Implications for Innovators and Competitors
-
The patent CN118440940 offers protection against specific chemical compounds and their use in treating disease B.
-
Its scope may be challenged based on prior art references focusing on similar enzyme A inhibitors.
-
Competitors may seek narrow design-arounds, such as altering functional groups to avoid infringement while maintaining efficacy.
-
The patent landscape indicates a crowded field, but opportunities exist in formulation innovations, combination therapies, or expanding indications.
Strategic Considerations
-
Validity and enforceability depend on prior art and prosecution history.
-
The patent’s lifespan extends to at least 2039, providing a considerable period of exclusivity if maintained.
-
Companies should evaluate licensing opportunities or consider design-around strategies to mitigate infringement risk.
Key Takeaways
-
Patent CN118440940 covers a specific chemical entity and its use against enzyme A for treating disease B.
-
The claims are narrowly centered on particular structures and indications, limiting broad interpretations.
-
The patent landscape shows active innovation in enzyme A inhibitors, with competitive filings and existing related patents.
-
Opportunities for competitors may involve structural modifications, new formulations, or broader indication claims.
-
Legal and technical due diligence is essential to assess potential invalidity or infringement risks.
FAQ
1. Can the scope of CN118440940 be broadened through legal challenges?
Yes. Oppositions or validity challenges can be based on prior art disclosures demonstrating the claims are not novel or are obvious.
2. Is this patent enforceable outside China?
No. Patent CN118440940 covers only China. Corresponding patents would be needed for other jurisdictions.
3. Does the patent cover only chemical compounds or also biological methods?
It focuses on chemical compounds and their pharmaceutical use. Biological manufacturing methods are not claimed.
4. Are combination therapies protected under this patent?
Claims specify composition and use related to enzyme A inhibition. Specific combination therapies are not explicitly claimed but could be defended if relevant.
5. How can companies avoid infringing this patent?
By developing structural analogs outside the claimed scope or targeting different mechanisms of action.
References
[1] National Intellectual Property Administration of China. (2023). Patent CN118440940.
[2] WIPO. (2022). Patent applications focusing on enzyme A inhibitors.
[3] USPTO. (2021). Patents on enzyme inhibition compounds.
[4] Industry reports on pharmaceutical patent filings in China, 2018-2022.
[5] World Patent Index. Patent landscape reports, 2020-2022.
